Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

489 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of Early Clozapine Treatment on Remission Rates in Acute Schizophrenia (The EARLY Trial): Protocol of a Randomized-Controlled Multicentric Trial.
Wagner E, Strube W, Görlitz T, Aksar A, Bauer I, Campana M, Moussiopoulou J, Hapfelmeier A, Wagner P, Egert-Schwender S, Bittner R, Eckstein K, Nenadić I, Kircher T, Langguth B, Meisenzahl E, Lambert M, Neff S, Malchow B, Falkai P, Hirjak D, Böttcher KT, Meyer-Lindenberg A, Blankenstein C, Leucht S, Hasan A. Wagner E, et al. Among authors: leucht s. Pharmacopsychiatry. 2023 Sep;56(5):169-181. doi: 10.1055/a-2110-4259. Epub 2023 Jul 28. Pharmacopsychiatry. 2023. PMID: 37506738 Free PMC article.
Associations Between Polygenic Risk Score Loading, Psychosis Liability, and Clozapine Use Among Individuals With Schizophrenia.
Lin BD, Pinzón-Espinosa J, Blouzard E, van der Horst MZ, Okhuijsen-Pfeifer C, van Eijk KR, Guloksuz S, Peyrot WJ, Luykx JJ; Genetic Risk and Outcome of Psychosis (GROUP) and Clozapine International Consortium (CLOZIN) Investigators. Lin BD, et al. JAMA Psychiatry. 2023 Feb 1;80(2):181-185. doi: 10.1001/jamapsychiatry.2022.4234. JAMA Psychiatry. 2023. PMID: 36542388 Free PMC article.
Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST).
Winter-van Rossum I, Weiser M, Galderisi S, Leucht S, Bitter I, Glenthøj B, Hasan A, Luykx J, Kupchik M, Psota G, Rocca P, Stefanis N, Teitelbaum A, Bar Haim M, Leucht C, Kemmler G, Schurr T; EULAST Study Group; Davidson M, Kahn RS, Fleischhacker WW. Winter-van Rossum I, et al. Among authors: leucht s, leucht c. Lancet Psychiatry. 2023 Mar;10(3):197-208. doi: 10.1016/S2215-0366(23)00005-6. Epub 2023 Jan 27. Lancet Psychiatry. 2023. PMID: 36716759 Clinical Trial.
Guideline for schizophrenia: implementation status and attitude toward an upcoming living guideline.
Khorikian-Ghazari N, Lorenz C, Güler D, Halms T, Röh A, Flick M, Burschinski A, Pielenz C, Salveridou-Hof E, Schneider-Axmann T, Schneider M, Wagner E, Falkai P, Gaebel W, Leucht S, Hasan A, Gaigl G. Khorikian-Ghazari N, et al. Among authors: leucht s. Eur Arch Psychiatry Clin Neurosci. 2023 Oct;273(7):1587-1598. doi: 10.1007/s00406-023-01568-z. Epub 2023 Feb 18. Eur Arch Psychiatry Clin Neurosci. 2023. PMID: 36808533 Free PMC article.
Conventional and living guideline for schizophrenia: barriers and facilitating factors in guideline implementation.
Lorenz C, Güler D, Halms T, Khorikian-Ghazari N, Röh A, Flick M, Burschinski A, Pielenz C, Salveridou-Hof E, Schneider-Axmann T, Schneider M, Wagner E, Falkai P, Gaebel W, Leucht S, Hasan A, Gaigl G. Lorenz C, et al. Among authors: leucht s. Eur Arch Psychiatry Clin Neurosci. 2023 Aug 15. doi: 10.1007/s00406-023-01663-1. Online ahead of print. Eur Arch Psychiatry Clin Neurosci. 2023. PMID: 37581691
Association of symptom severity and cerebrospinal fluid alterations in recent onset psychosis in schizophrenia-spectrum disorders - An individual patient data meta-analysis.
Campana M, Yakimov V, Moussiopoulou J, Maurus I, Löhrs L, Raabe F, Jäger I, Mortazavi M, Benros ME, Jeppesen R, Meyer Zu Hörste G, Heming M, Giné-Servén E, Labad J, Boix E, Lennox B, Yeeles K, Steiner J, Meyer-Lotz G, Dobrowolny H, Malchow B, Hansen N, Falkai P, Siafis S, Leucht S, Halstead S, Warren N, Siskind D, Strube W, Hasan A, Wagner E. Campana M, et al. Among authors: leucht s. Brain Behav Immun. 2024 Apr 10;119:353-362. doi: 10.1016/j.bbi.2024.04.011. Online ahead of print. Brain Behav Immun. 2024. PMID: 38608742 Free article.
Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study.
Kahn RS, Winter van Rossum I, Leucht S, McGuire P, Lewis SW, Leboyer M, Arango C, Dazzan P, Drake R, Heres S, Díaz-Caneja CM, Rujescu D, Weiser M, Galderisi S, Glenthøj B, Eijkemans MJC, Fleischhacker WW, Kapur S, Sommer IE; OPTiMiSE study group. Kahn RS, et al. Among authors: leucht s. Lancet Psychiatry. 2018 Oct;5(10):797-807. doi: 10.1016/S2215-0366(18)30252-9. Epub 2018 Aug 13. Lancet Psychiatry. 2018. PMID: 30115598 Clinical Trial.
Generalizability of the Results of Efficacy Trials in First-Episode Schizophrenia: Comparing Outcome and Study Discontinuation of Groups of Participants in the Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial.
Nasib LG, Winter-van Rossum I, Zuithoff NPA, Boudewijns ZSRM, Leucht S, Kahn RS. Nasib LG, et al. Among authors: leucht s. J Clin Psychiatry. 2023 Mar 29;84(3):22m14531. doi: 10.4088/JCP.22m14531. J Clin Psychiatry. 2023. PMID: 36988483 Clinical Trial.
489 results